

FORM PTO-1449A		Attorney Docket: 4874-7001	Serial No.: 10/567,113
INFORMATION DISCLOSURE CITATION		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: 1752

U.S. PATENT / PUBLICATION DOCUMENTS

Examiner Initial		Patent/Publication Number	Publication/Issue Date	Name	Filing Date
	1.				
	2.				
	3.				
	4.				
	5.				
	6.				
	7.				
	8.				
	9.				
	10.				
	11.				
	12.				
	13.				
	14.				

FOREIGN PATENT DOCUMENTS

Examiner Initial		Patent Number	Publication Date	Country	Copy Filed	Translation
PL	15.	EP0612733 A1	08/31/1994	EP	<input checked="" type="checkbox"/> Yes	N/A
1	16.	EP0617024 A1	02/12/1994	EP	<input checked="" type="checkbox"/> Yes	N/A
	17.	EP1203587 A1	05/08/2002	EP	<input checked="" type="checkbox"/> Yes	N/A
	18.	JP50046697	04/25/1975	JP	<input checked="" type="checkbox"/> Yes	Abstract
Y	19.	RU2169139	06/20/2001	RU	<input checked="" type="checkbox"/> Yes	Abstract
PL	20.	WO 02/09681 A2	02/07/2002	WIPO	<input checked="" type="checkbox"/> Yes	N/A

Examiner	Date Considered	
EXAMINER: <i>Patricia Lewis</i> Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

FORM PTO-1449A

INFORMATION DISCLOSURE CITATION

Attorney Docket:
4874-7000Serial No.:
10/567,113Applicant:
ZHILOV, et al.Filing Date:
August 4, 2003Group Art Unit:
T/B/A

U.S. PATENT PUBLICATION DOCUMENTS

Examiner Initial	Patent/Publication Number	Publication/Issue Date	Name	Filing Date
1.				
2.				
3.				
4.				
5.				
6.				
7.				
8.				
9.				
10.				
11.				
12.				
13.				
14.				

FOREIGN PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication Date	Country	Copy Filed	Translation
K	2014077 C1	06-15-1994	Russia	<input checked="" type="checkbox"/> Yes	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
15.				<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
16.				<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
17.				<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
18.				<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
19.				<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
20.				<input type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No

Examiner

Patrick Lewis


Date Considered

*12-28-07*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1449B		Attorney Docket: 4874-7001	Serial No.: 10/567,113
INFORMATION DISCLOSURE CITATION		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
PL	1.	Trump B.F., Berezesky I.K. "The role of altered [Ca ²⁺] in regulation in apoptosis, oncosis and necrosis". Biochem. Biophys. Acta, 1996, v. 1313, p. 173-178.
	2.	Roos A., Boron W.F. "Intracellular pH". Physiol. Rev., 1981, v. 61, p. 296-434.
	3.	Akotov V.S., Grobova M.E., Rkshevoi Yu.V. "Intracellular pH and substrate dependence of proliferation of fibroblasts of Chinese hamster". Cytology, 1991, 33 (7), p. 86-94.
	4.	Gillies R.G., Martinez-Zaguilan R., Peterson E.P., Perona R. "The role of intracellular pH in mammalian cell proliferation". Cell. Physiol. Biochem., 1992, 2, p.159-179.
	5.	Akatov V.S., Grobova M.E. "Activation of intracellular pH regulating systems upon cell adhesion to solid substrate". Biol. Membr., 1993, v.6, p. 917-934.
	6.	Kapus A., Romanek R., Qu A.Y., Rotstein O.O., Grinstein S.A. "pH-sensitive and voltage-dependent proton conductance in the plasma membrane of macrofages". J. Gen. Physiol., 1993, vol. 02 (4), p. 723-760.
	7.	Demareux N., Downey G., Waddell T., Grinstein S. "Intracellular pH regulator during spreading of human neutrophils", J.Cell. Biol., 1996, v. 133, p. 1381-1402.
	8.	Tannock I.A., Rotin D. "Acid pH in tumors and its potential for therapeutic exploration". Cancer Res., 1989, v.49, p. 4373-4384.
	9.	Stabbs M., Rodrigues L., Howl F.A., Wang I., Joeng K.S., Veech R.L., Griffiths J.R. "Metabolic consequences of a reversed pH gradient in rat tumors". Cancer Res., 1994, v.54, p. 4011-4016.
Y	10.	Mashkovsky M.D., "Medicinal Agents". Moscow, Medicine, 1993, part II, p. 137-140.
PL	11.	Taguchi Hiroshi. "A new fluorometric assay method for guinolinic acid". Analitic Biochemistry, 1983, 131 (1), p. 194-197

Examiner Signature		Date Considered	12-28-07
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449B		Attorney Docket: 4874-7001	Serial No.: 10/567,113
INFORMATION DISCLOSURE CITATION		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

PL	12.	Huntress E.H., Stanley L.N., Parker A.S. "The preparation of 3-Aminophthalhydrazide for use in the Demonstration of Chemiluminescence", J. Am. Chem. Soc., 1994, v. 56, p. 241-242.
1	13.	Zyczynska - Baloniak I., Czajka R., Zinkowska E., "Synthesis of Derivatives of 4-Hydroxypyrazine-[2,3-d]pyridazine-1-one. Polish Journal of Chemistry. 1978, v. 52, p. 2461-2465.
1	14.	Kormendy K., Ruff F. "Pyridazines condensed with a Heteroring. III", Acta Chimica Hungarica. 1990, 127 (2), p. 253-262.
1	15.	Yurugi S., Hieda M. "Studies on the synthesis of N- Heterocyclic Compounds". Chemistry, Pharmaceutic Bull., 1972, v. 20 (7), p 1522-1527. ibid., p. 1513-1521.
1	16.	Seo E., Kuwana T. "Polarography of cyclic Hydrazides", J. Electroanal. Chem., 1963, v. 6, p. 417-418.
1	17.	Lund H. "Polarographic and electropreparative reduction of 1(2H)-phthalazines, 2,3-dihydro-1,4 phthalazindiones and related compounds", Coll. Czechoslow. Chem. Com., 1965, v. 30. p. 4237-4249.
1	18.	Ganz M.B. et all. "Argininvasopressin exchangers of pH, regulation in the presence of HCO ₃ ⁻ by stimulating three acid-base transport systems", Nature, 1989, v. 337, p. 648-651.
V PL	19.	Rogachev B., Hausmann M.J., Julzari R., Weiler H., Holmes C., Falct D., Chaimovitz C., Douvdevani A. "Effect of bicarbonat-based dialysis solution on intracellular pH (pH _i) and TNF-alpha production by peritoneal macrophages, Perit. Dial. Int., 1997, Nov-Dec, 17 (6), p. 543-553.

Examiner Signature		Date Considered	PL-28-07
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449B		Attorney Docket: 4874-7001	Serial No.: 10/567,113
INFORMATION DISCLOSURE CITATION		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
PL	20.	Bidani A., Heming T.A. "Effect of concanavalin A on Na ⁺ -dependent and Na ⁺ -independent mechanism for H ⁺ extrusion in alveolar macrophages", Lung., 1998, 176 (1), p. 25-31.
	21.	Swallow C.J., Grinstein S., Sudsbury R.A., Rotstein O.D. "Relative roles of Na ⁺ /H ⁺ exchange and vacuolar-type H ⁺ ATPases in regulating cytoplasmic pH and Function in murine peritoneal macrophages", J. Cell. Physiol., 1993, 157 (3), p. 453-460.
	22.	Koshevoi Yu.V., Akatov V.S., Grobova M.E., "Microspectrofluorimeter for measuring endocellular pH (micro pH)". Devices and equipment for studies in the field of physical-and-chemical biology and biotechnology. Pushchino, 1990. P. 8-14.
	23.	Thomas J.A., Bushbaum R.N., Zimniak A.w Racker E. "Intracellular pH measurements in Ehrlich ascites tumor cells utilizing spectroscopic probe generated <i>in situ</i> ", Biochemistry, 1979, v. 18, p. 2210-2218.
	24.	Li J., Eastman A. "Apoptosis in an interleukin-2-dependend cytotoxic T-lymphocyte cell line is associated with intracellular acidification", J.Biol. Chem., 1995, v. 270., Number 7, p. 3203-3211.
↓	25.	Solovieva M.E., Akatov V.S., Leshchenko V.V., Kudryavtsev V.A. "The mechanism of destruction of cells of myeloma NS/O in culture". Proceeding of the Russian Academy of Sciences, 1998, 2, p. 194-189.
PL	26.	Zhu W.-H., Loh T.-T. "Effects of Na ⁺ /H ⁺ antiport and intracellular pH in the regulation of HL-60 cell apoptosis", Biochim. Biophys. Acta, 1995, v. 1269, p. 122-128.

Examiner Signature	<i>Atsuo Iwai</i>	Date Considered	12-28-07
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.87 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449B		Attorney Docket: 4874-7001	Serial No.: 10/567,113
INFORMATION DISCLOSURE CITATION		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A
NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	

<i>PL</i>	27.	Brenton P.D. "Mechanistic Aspect of Diazaquinone Chemiluminescence", Aust. J. Chem., 1984, v. 37, p. 1001-1008.
	28.	Nishikimi M. Rao N.A. and Yagi K. "The occurrence of superoxide anion in the reaction of reduced phenasine methosulfate and molecular oxygen". Biochem. Biophys. Res. Commun, 1972, v. 46, p. 849-855.
	29.	Rahman S., Ali Khan R., Kumar A. "Experimental study of the morphine dead addiction properties of Delphinium nudatum Wall//BMC Complement Altern". Med. 2002, v. 29, p. 1-6.
	30.	Dum J., Blasig J., Herz A. Buprenorphine: "Demonstration of physical dependence liability". Eur. J. Pharmacol., 1981, v. 70. p. 293-300.
	31.	Misko T.R., Schilling R.J., Salvemini D. et al. "A fluorometric assay for the measurement of nitrite of biological samples". Anal. Biochem., 1993, v. 214, p. 11-16.
	32.	Bredt and Snyder. "Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum". Proc. Natl. Acad. Sci. USA, 1989, v. 86, p. 9030-9033.
	33.	Kiss J.P., Vizi E.S., "Nitric oxide: a novel link between synaptic and nonsynaptic transmission," Trends Neurosci., 2001, Apr., 24 (4):211-5.
	34.	Paul I.A., Skolnick P., "Glutamate and depression: clinical and preclinical studies," Ann. N Y Acad. Sci., 2003, Nov; 1003:250-72.
<i>PL</i>	35.	Girgin Sagin F., Sozmen E.Y., Ersoz B., Mentes G., "Link between monoamine oxidase and nitric oxide," Neurotoxicology, 2004, Jan., 25 (1-2): 91-9.
<i>PL</i>	36.	Vizi E.S., "Role of high-affinity receptors and membrane transporters in nonsynaptic

Examiner Signature	<i>Patricia Lewis</i>	Date Considered	<i>12-28-07</i>
--------------------	-----------------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449B		Attorney Docket: 4874-7001	Serial No.: 10/567,113
INFORMATION DISCLOSURE CITATION		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
--------------------	-----------------------	---

		communication and drug action in the central nervous system," Pharmacol. Rev., 2000, Mar., 52 (1): 63-89.
	37.	Liu Y., "Nitric oxide effect dopaminergic processes", Adv. Neuroimmunol., 1996, 6 (3): 259-64.
	38.	Chiavegatto S., Nelson R.J., "Interaction of nitric oxide and serotonin in aggressive behavior," Horm. Behav., 2003, Sep., 44 (3): 233-41.
	39.	Pfaus J.G., "Neurobiology of sexual behavior", Curr. Opin. Neurobiol., 1999, Dec., 9 (6): 751-8.
	40.	Stefano G.B., "Autoimmunovascular regulation: morphine and anandamide and anandamide stimulated nitric oxide release", J.Neuroimmunol., 1998, Mar., 15, 83 (1-2): 70-6.
	41.	Tayfun Uzbay I., "Oglesby M.W. Nitric oxide and substance dependence," Neurosci. Biobehav. Rev., 2001, Jan., 25 (1): 43-52.
	42.	Kiss J.P. "Role of nitric oxide in the regulation of monoaminergic neurotransmission", Brain Res. Bull., 2000, Aug., 52 (6): 459-66.
	43.	Mandel S., Grunblatt E., Riederer P., Gerlach M., Levites Y., "Youdim M.B. Neuroprotective strategies in Parkinson's disease: an update on progress", CNS Drugs, 2003, 17 (10): 729-62.
	44.	Ujike H., "Advanced findings on the molecular mechanisms for behavioral sensitization to psychostimulants", Nippon Yakurigaku Zasshi., 2001, Jan., 117 (1): 5-12.
	45.	Olesen J., Jansen-Olesen I., "Nitric oxide mechanisms in migraine." Pathol. Biol., Paris, 2000, Sep., 48 (7): 648-57.

Examiner Signature	<i>Patricia L. Lew</i>	Date Considered	12-28-07
--------------------	------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449B		Attorney Docket: 4874-7001	Serial No.: 10/567,113
INFORMATION DISCLOSURE CITATION		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A
NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	

<i>PL</i>	46.	Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G., "Dopamine receptors: from structure to function", <i>Physiol. Rev.</i> , 1998, Jan., 78 (1): 189-225.	
	47.	<i>Zawilska J.B.</i> "Dopamine receptors-structure, characterization and function", <i>Postepy, Hig. Med. Dosw.</i> , 2003, 57 (3): 293-322.	
<i>PL</i>	48.	Fagen Z.M., Mansvelder H.D., Keath J.R., Mc. Gehee D.S., "Short- and long-term modulation of synaptic inputs to brain reward areas by nicotine", <i>Ann. NY Acad. Sci.</i> , 2003, Nov., 1003: 185-95.	
	49.	Ujike H., "Molecular biology of drug dependence and behavioral sensitization", <i>Seishin Shinkeigaku Zasshi.</i> , 2002, 104 (11): 1055-68.	
<i>PL</i>	50.	Wolf M.E., Mangiavacchi S., Sun X., "Mechanisms by which dopamine receptors may effect synaptic plasticity", <i>Ann. NY Acad. Sci.</i> , 2003, Nov., 1003: 241-9.	
	51.	Kosten T.R., George T.P., Kosten T.A., "The potential of dopamine agonists in drug addiction", <i>Expert Opin. Investig. Drugs</i> , 2002, Apr., 11 (4): 491-9.	
<i>PL</i>	52.	Pearlson G.D. "Neurobiology of schizophrenia", <i>Ann. Neurol.</i> , 2000, Oct., 48 (4):556-66.	
	53.	Abi-Dargham A., Moore H., "Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia", <i>Neuroscientist</i> , 2003, Oct., 9 (5): 404-16).	
<i>PL</i>	54.	Conley R.R., Kelly D.L. "Current status of antipsychotic treatment" <i>Curr. Drug Target CNS. Neurol. Disord.</i> , 2002, Apr., 1 (2): 123-8.	
	55.	Taylor D.P., Riblet L.A., Stanton H.C., Eison A.S., Eison M.S., Temple DL Jr.. "Dopamine and antianxiety activity", <i>Pharmacol. Biochem. Behav.</i> , 1982, 17, Suppl. 1: 25-35.	


Examiner Signature	<i>Taylor Lee</i>	Date Considered	12-28-07
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449B		Attorney Docket: 4874-7001	Serial No.: 10/567,113
INFORMATION DISCLOSURE CITATION		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A
NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	

	56.	Kapur S., Mamo D. "Half a century of antipsychotics and still a central role for dopamine D2 receptors", <i>Prog. Neuropsychopharmacol. Biol. Psychiatry</i> , 2003, Oct., 27 (7): 1081-90.
	57.	Taguchi Hiroshi. "A new fluorometric assay method for quinolinic acid". <i>Analitic Biochemistry</i> , 1983, 131 (1), p. 194-197.
	58.	Huntress E.H., Stanley L.N., Parker A.S. "The preparation of 3-Aminophthalhydrazide for use in the Demonstration of Chemiluminescence", <i>J. Am. Chem. Soc.</i> , 1994, v. 56, p. 241-242.
	59.	Zyczynska - Baloniak I., Czajka R., Zinkowska E., "Synthesis of Derivatives of 4-Hydroxypyrazine-[2,3-d]pyridazine-1-one. Polish Journal of Chemistry. 1978, v. 52, p. 2461-2465.
	60.	Kormendy K., Ruff F. "Pyridazines condensed with a Heteroring. III", <i>Acta Chimica Hungarica</i> . 1990, 127 (2), p. 253-262.
	61.	Yurugi S., Hieda M. "Studies on the synthesis of N- Heterocyclic Compounds". <i>Chemistry, Pharmaceutic Bull.</i> , 1972, v. 20 (7), p 1522-1527. <i>ibid.</i> , p. 1513-1521.
	62.	Dum J., Blasig J., Herz A. "Buprenorphine: demonstration of physical dependence liability", <i>Eur. J. Pharmacol.</i> , 1981, V. 70, p. 293-300.
	63.	Rahman S., Ali Khan R., Kumar A., "Experimental study of the morphine de-addiction properties of Delphinium nudatum Wall", <i>BMC Complement Altern. Med.</i> , 2002, V.29, p.1-6.
	64.	Blasig J., Herz A., Reinhold K., Zieglsberger S. "Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats", <i>Psychopharmacologia</i> , Berlin, 1973, V.33,

Examiner Signature		Date Considered	12-28-07
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449B		Attorney Docket: 4874-7001	Serial No.: 10/567,113
INFORMATION DISCLOSURE CITATION		Applicant: ZHILOV, et al.	
		Filing Date: August 4, 2003	Group Art Unit: T/B/A

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
--------------------	-----------------------	---

<i>PK</i>		p.19-38.
	65.	Rahman S., Ali Khan R., Kumar A. "Experimental study of the morphine de-addiction properties of Delphinium nudatum" Wall, BMC Complement Altern. Med., 2002, V.29, p.1-6.
	66.	Misko T.R., Schilling R.J., Salvemini D. et al. "A fluorometric assay for the measurement of nitrite in biological samples", Anal. Biochem., 1993, V. 214, p.11-16.
	67.	Lei B., Adachi N., Nagaro T., Arai T. "Measurement of total nitric oxide metabolite (NO (x) (-)) levels in vivo. Brain", Res. Protoc., 1999, V. 4, p. 415-419.
	68.	Bredt M., Snyder S. "Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum", Proc. Natl. Acad. Sci., USA, 1989, V.86, p.9030-9033.
	69.	Bradford M. M. "A rapid and sensitive method for quantitation of microgram quantities of protein using the principle of protein binding" Anal. Biochem., 1976, V. 72, p. 248-254.
	70.	Giuliano F., Allard J. "Dopamine and male sexual function" Eur. Urol., 2001, 40 (6), 601-608.
	71.	Giuliano F., Allard J., Rampin O. et. al. "Pro-erectile effect of systemic apomorphine: existence of a spinal site action" J. Urol., 2002, 167 (1), 402-406.
<i>PK</i>	72.	Brien S.E., Smallegange C., Gofton W.T., et.al. "Development of a rat model of sexual performance anxiety: effect of behavioral and pharmacological hyperadrenergic stimulation on apomorphine-induced erections" Int. J. Impot. Res., 2002, 14 (2), 107-115.

Examiner Signature	<i>Patricia Lee</i>	Date Considered	12-28-07
--------------------	---------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



FORM PTO-1449A

INFORMATION DISCLOSURE CITATION

Attorney Docket:
4874-7001

Serial No.
10/567,113

Applicant:
Zhilov et al.

Filing Date:
August 3, 2004

Group Art Unit:
Unknown

U.S. PATENT / PUBLICATION DOCUMENTS

Examiner Initial		Patent/Publication Number	Publication/Issue Date	Name	Filing Date
PL	1.	5719151	02-1998	Shall et al.	
1	2.	5753706	05-1998	Hsu	
	3.	5196432	03-1993	Crichlow	
	4.	5597820	01-1997	Hori et al.	
↓	5.	5723496	03-1998	Nakada	
PL	6.	5256660	10-1993	Swan	
	7.				
	8.				
	9.				
	10.				
	11.				
	12.				
	13.				
	14.				

FOREIGN PATENT DOCUMENTS

Examiner Initial		Patent Number	Publication Date	Country	Copy Filed	Translation
PL	15.	2 211 036	08-2003	Russia	<input checked="" type="checkbox"/> Yes (Abstract Only)	
1	16.	2 163 122	02-2001	Russia	<input checked="" type="checkbox"/> Yes (Abstract Only)	
	17.	2 168 511	08-1998	Russia	<input checked="" type="checkbox"/> Yes (Abstract Only)	
↓	18.	05-078356	03-1993	Japan	<input checked="" type="checkbox"/> Yes (Abstract Only)	
PL	19.	2 185 173	07-2002	Russia	<input checked="" type="checkbox"/> Yes (Abstract Only)	

Examiner	<i>Patrick Len</i>	Date Considered	<i>12-28-07</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

10/567113
IAP9 Rec'd PCT/PTO 03 FEB 2006
Page 2

FORM PTO-1449A INFORMATION DISCLOSURE CITATION		Attorney Docket: 4874-7001	National Stage of International Application No. PCT/RU2004/000298	
		Applicant: Zhilov et al.		
		International Filing Date: August 3, 2004	Group Art Unit: Unassigned	

U.S. PATENT / PUBLICATION DOCUMENTS

Examiner Initial	Patent/Publication Number	Publication/Issue Date	Name	Filing Date
PL	1. 4612316	09-1986	Andersson et al.	
1	2. 4727079	02-1988	Bodor	
	3. 4904676	02-1990	Rae et al.	
	4. 4547507	10-1985	Clements-Jewery	
	5. 4600714	07-1986	Gaitanopoulos et al.	
	6. 5281594	01-1994	Piercey et al.	
	7. 5889010	03-1999	Sanner et al.	
	8. 5883094	03-1999	Sanner et al.	
W	9. 6521623	02-2003	Monferini et al.	
PL	10. 4650805	03-1987	Jaen et al.	
	11.			
	12.			
	13.			
	14.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication Date	Country	Copy Filed	Translation
PL	15. 1 203 587 A	05-2002	Europe	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
1	16. 2 169 139 C	06-2001	Russia	<input checked="" type="checkbox"/> Yes	<input checked="" type="checkbox"/> Yes (Abstract Only)
	17. 0 617 024 A	09-1994	Europe	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
	18. 0 612 733 A	08-1994	Europe	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
W	19. 02/09681 A	02-2002	WIPO	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> Yes <input type="checkbox"/> No
PL	20. 50 046697 A	04-1975	Japan	<input checked="" type="checkbox"/> Yes	<input checked="" type="checkbox"/> Yes (Abstract Only)

Examiner	Date Considered
EXAMINER: <i>[Signature]</i> Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	